title: Comparison of immunosuppressive and cytotoxic cells in angiosarcoma: development of a possible supportive therapy for angiosarcoma.
abstract: An imbalance of immunosuppressive and cytotoxic cells plays an important role in inhibiting the anti-tumor immune response of the tumor-bearing host. The purpose of this study was to elucidate the involvement of immunosuppressive cells, such as regulatory T cells and CD163+ M2 macrophages as well as cytotoxic cells, such as granulysin-bearing cells and TIA-1+ cells in cutaneous angiosarcoma (AS) by immunohistochemical staining. In addition we evaluated the potencies of bisphosphonate, which was previously reported to suppress the expression of matrix metalloproteinase 9 (MMP-9), as a supportive therapy for AS together with docetaxel in 6 cases of cutaneous AS. These findings suggest that a high number of immunosuppressive cells might be related to the prognosis of AS, and that a combination of docetaxel with bisphosphonate risedronate sodium might be effective for MMP-9-expressing AS.
authors.affiliation: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Kambayashi
authors.forename: Taku
authors.initials: T
authors.lastname: Fujimura
authors.forename: Sadanori
authors.initials: S
authors.lastname: Furudate
authors.forename: Akira
authors.initials: A
authors.lastname: Hashimoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Haga
authors.forename: Setsuya
authors.initials: S
authors.lastname: Aiba
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001081:Apyrase / Q000032:analysis; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis; D006394:Hemangiosarcoma / Q000737:chemistry / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D006801:Humans; D008264:Macrophages / Q000737:chemistry; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000032:analysis; D039102:Poly(A)-Binding Proteins / Q000032:analysis; D011956:Receptors, Cell Surface / Q000032:analysis; D000068296:Risedronic Acid; D012878:Skin Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D000074019:T-Cell Intracellular Antigen-1; D013602:T-Lymphocytes, Cytotoxic / Q000737:chemistry; D050378:T-Lymphocytes, Regulatory; D043823:Taxoids / Q000627:therapeutic use; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000945:Antigens, Differentiation, T-Lymphocyte; D000970:Antineoplastic Agents; D000098902:CD163 Antigen; D004791:Enzyme Inhibitors; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; C075005:GNLY protein, human; D039102:Poly(A)-Binding Proteins; D011956:Receptors, Cell Surface; D000074019:T-Cell Intracellular Antigen-1; C071558:TIA1 protein, human; D043823:Taxoids; D000077143:Docetaxel; D020780:Matrix Metalloproteinase 9; D001081:Apyrase; C067869:CD39 antigen; D000068296:Risedronic Acid; D012968:Etidronic Acid